Table 2.
Characteristics | Yes (N=97) | No (N=103) | Univariate Subdistribution HR | p* | Multivariate Subdistribution HR | p* |
---|---|---|---|---|---|---|
N (%) | N (%) | (95% CI) | (95% CI) | |||
Sex | ||||||
Female | 35 (57) | 27 (43) | ||||
Male | 62 (45) | 76 (55) | 0.70 (0.46 – 1.06) | 0.096 | ||
Mean age (STD) | 59 (12) | 60 (10) | 1 (0.98 – 1.02) | 0.661 | ||
BMI (kg/m2) | ||||||
Normal weight (20–25) | 37 (40) | 56 (60) | - | |||
Underweight (≤20) | 8 (25) | 24 (75) | 0.55 (0.26 – 1.15) | 0.109 | 0.70 (0.28 – 1.72) | 0.433 |
Overweight/Obese (>25) | 52 (69) | 23 (31) | 2.44 (1.61 – 3.71) | <0.001 | 1.6 (1.03 – 2.48) | 0.036 |
Smoking history | ||||||
Non-user | 21 (64) | 12 (36) | - | |||
Former/current user | 76 (46) | 91 (55) | 0.54 (0.33 – 0.88) | 0.014 | 0.64 (0.39 – 1.07) | 0.088 |
Alcohol history | ||||||
Non-user | 47 (48) | 50 (52) | ||||
Former/current user | 50 (49) | 53 (51) | 0.92 (0.62 – 1.36) | 0.671 | ||
HN-CCI score | ||||||
0 (none) | 67 (46) | 80 (54) | ||||
1 (mild) | 23 (58) | 17 (42) | 1.27 (0.80 – 2.01) | 0.304 | ||
2 (moderate) | 7 (54) | 6 (46) | 1.18 (0.58 – 2.42) | 0.651 | ||
Prior radiation | ||||||
Yes | 20 (29) | 50 (71) | - | |||
No | 77 (59) | 53 (41) | 2.68 (1.65 – 4.35) | <0.001 | 3.02 (1.34 – 6.83) | 0.008 |
Prior chemotherapy | ||||||
Yes | 18 (32) | 39 (68) | - | |||
No | 79 (55) | 64 (45) | 2.17 (1.33 – 3.56) | 0.002 | 0.67 (0.28 – 1.62) | 0.375 |
T stage | ||||||
0–2 | 36 (68) | 17 (32) | ||||
3–4 | 61 (42) | 86(59) | 0.47 (0.31 – 0.71) | <0.001 | ||
N stage | ||||||
0 | 47 (54) | 40 (46) | ||||
1 | 22 (69) | 10 (31) | 1.61 (0.95 – 2.71) | 0.074 | ||
2–3 | 28 (35) | 53 (65) | 0.56 (0.36 – 0.89) | 0.014 | ||
AJCC stage (7th ed.) | ||||||
I-II | 21 (72) | 8 (28) | - | |||
III-IV | 76 (44) | 95 (56) | 0.48 (0.30 – 0.78) | 0.003 | 0.92 (0.50 – 1.69) | 0.777 |
Tumor laterality | ||||||
Bilateral | 16 (28) | 42 (72) | - | |||
Midline | 13 (46) | 15 (54) | 1.85 (0.92 – 3.73) | 0.084 | 1.34 (0.65 – 2.79) | 0.429 |
Unilateral | 68 (60) | 46 (40) | 2.84 (1.69 – 4.78) | <0.001 | 1.07 (0.54 – 2.11) | 0.846 |
Tumor extension | ||||||
Extension to adjacent site | 48 (45) | 59 (55) | ||||
No extension | 49 (53) | 44 (47) | 1.39 (0.94 – 2.06) | 0.103 | ||
Preoperative G-tube dependence | ||||||
Yes | 9 (18) | 41 (82) | - | |||
No | 88 (59) | 62 (41) | 4.46 (2.31 – 8.64) | <0.001 | 2.08 (0.95 – 4.56) | 0.066 |
Preoperative diet | ||||||
Abnormala | 34 (30) | 81 (70) | - | |||
Normal PO | 63 (74) | 22 (26) | 3.78 (2.50 – 5.72) | <.0001 | 1.53 (0.82 – 2.83) | 0.178 |
Flap donor site | ||||||
ALT/Scap/Latissimus/AMT | 50 (38) | 82 (62) | - | |||
Radial/ulnar forearm | 32 (73) | 12 (27) | 3.39 (2.10 – 5.47) | <0.001 | 1.90 (1.13 – 3.19) | 0.016 |
Fibula | 15 (63) | 9 (37) | 2.02 (1.22 – 3.34) | 0.007 | 1.17 (0.63 – 2.16) | 0.625 |
Amount of tongue resected | ||||||
Partial or hemi-oral glossectomy | 49 (64) | 28 (36) | - | |||
Base of tongue with/without hemi-oral glossectomy | 21 (46) | 25 (54) | 0.53 (0.32 – 0.88) | 0.014 | 0.71 (0.39 – 1.30) | 0.269 |
Subtotal or total glossectomy | 10 (24) | 32 (76) | 0.24 (0.12 – 0.47) | <0.001 | 0.41 (0.18 – 0.97) | 0.043 |
Composite | 17 (49) | 18 (51) | 0.56 (0.34 – 0.94) | 0.027 | 0.47 (0.27 – 0.81) | 0.007 |
Hypoglossal nerve removed | ||||||
Yes | 22 (32) | 46 (68) | - | |||
No | 75 (57) | 57 (43) | 2.31 (1.47 – 3.64) | <0.001 | 1.43 (0.85 – 2.42) | 0.183 |
Postoperative radiation | ||||||
Yes | 72 (49) | 75 (51) | ||||
No | 25 (47) | 28 (53) | 1.08 (0.69 – 1.71) | 0.730 | ||
Postoperative chemoradiation | ||||||
Yes | 40 (41) | 57 (59) | - | |||
No | 57 (55) | 46 (45) | 1.68 (1.13 – 2.51) | 0.010 | 1.87 (1.17 – 2.99) | 0.009 |
Abbreviations: HR, hazards ratio; CI, confidence interval; STD, standard deviation; AJCC, American Joint Committee on Cancer; BMI, body mass index; HN-CCI, The Head and Neck Charlson Comorbidity Index; ALT, anterolateral thigh; AMT, anteromedial thigh; Scap, parascapular; PO, per os; G-tube, gastrostomy tube
Clinical significance defined as p<0.05
Abnormal diet defined as modified PO to liquids or soft diet or any G-tube use